The Effect and Safety of Recombinant Fibroblast Growth Factor-1 for Carpal Tunnel Syndrome

Launched by TRI-SERVICE GENERAL HOSPITAL · Mar 18, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for Carpal Tunnel Syndrome (CTS), a condition that causes pain and numbness in the hand due to pressure on a nerve in the wrist. The treatment being tested is called ES135, a special protein that may help promote nerve healing and growth. Researchers hope that this therapy can improve symptoms for people suffering from CTS, especially those who have had symptoms for at least three months.

To participate in this trial, you need to be between 18 and 80 years old and have been diagnosed with CTS through a specific nerve test. However, if you have severe CTS or certain other medical conditions, you may not be eligible. If you join the study, you can expect to receive the treatment and be monitored for its effects on your symptoms. This trial is currently recruiting participants, so if you or someone you know is interested, it could be a chance to explore a new option for relief from CTS.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age between 18-80 year-old.
• • Diagnosis was confirmed by using an electrophysiological study
• • CTS symptoms for more than 3 months.
• Exclusion Criteria:
• • Severe CTS
• • Allergy to ES135
• • Pregnancy
• • Inflammation status
• • Cervical radiculopathy
• • Polyneuropathy, brachial plexopathy
• • Thoracic outlet syndrome
• • Previously undergone wrist surgery or steroid/platelet-rich plasma injection for CTS within 12 months